Gibson Dunn has advised Arrowhead Pharmaceuticals on the deal. Arrowhead Pharmaceuticals and Novartis have entered into a global license and collaboration agreement concerning ARO-SNCA, Arrowhead’s preclinical...
Arrowhead and Novartis Sign Global Licensing Agreement for Preclinical RNA Therapy
Arcosa’s $1.2 Billion Acquisition of Construction Materials Business of Stavola Holding Corporation
Gibson, Dunn & Crutcher and Kirkland & Ellis advised Arcosa, Inc. on the transaction. Arcosa, Inc. (NYSE: ACA) (“Arcosa,” the “Company”), a provider of infrastructure-related products...